Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02031237 · ClinicalTrials.gov registry record
MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy
A clinical trial of Brain Metastases, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- 52
- Enrollment target
- 1
- Study location
NCT02031237: Completed study of Brain Metastases, sponsored by University of Michigan Rogel Cancer Center.
NCT02031237 is a study of Brain Metastases that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 52 participants, below the 212-participant average among 67 other Brain Metastases trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02031237, a study of Brain Metastases, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to assess changes in vascular permeability in the brain tumor, and in the surrounding brain, due to radiation therapy, using Magnetic Resonance Imaging (MRI).
Primary Outcome
Fifty metastatic lesions from 21 patients received WBRT and 14 lesions from 9 patients treated by SRS were analyzed. Permeability of BTB (Blood-Tumor-Barrier) was quantified by the transfer constant, Ktrans, derived from dynamic contrast enhanced (DCE)-MRI that were acquired pre, 1-2 weeks after starting, and 1-month post-radiotherapy. A percentage volume of the BM with Ktrans \>0.005 min-1 (%Vall) was used to evaluate the extent of BTB opening pre-RT and subsequent changes after receiving radio
Conditions Studied
Interventions
- RADIATION Fractionated Stereotactic Radiation Therapy (FSRT)
- RADIATION Single Fraction Stereotactic Radiosurgery (SRS)
- RADIATION Fractionated Whole Brain Radiation Therapy (WBRT)
- DEVICE Magnetic Resonance Imaging (MRI) Assessments
Study Locations (1)
Michigan
- University of Michigan Hospital - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2005-04 |
| Est. Completion | 2014-12 |
What the finished NCT02031237 record still lists
NCT02031237 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 212-participant average among 67 other Brain Metastases trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Brain Metastases appearing as the primary indexed condition, and to 4 interventions - of which Fractionated Stereotactic Radiation Therapy (FSRT) is the first listed.
NCT02031237 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT02031237 about?
NCT02031237 is a clinical study titled "MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy". This study aims to assess changes in vascular permeability in the brain tumor, and in the surrounding brain, due to radiation therapy, using Magnetic Resonance Imaging (MRI).
What is the current status of trial NCT02031237?
This trial is currently completed. The enrollment target is 52 participants. The study started on 2005-04. Estimated completion is 2014-12.
What conditions does trial NCT02031237 study?
This clinical trial studies the following conditions: Brain Metastases.
What interventions are being tested in trial NCT02031237?
The interventions under investigation include: Fractionated Stereotactic Radiation Therapy (FSRT) (RADIATION), Single Fraction Stereotactic Radiosurgery (SRS) (RADIATION), Fractionated Whole Brain Radiation Therapy (WBRT) (RADIATION), Magnetic Resonance Imaging (MRI) Assessments (DEVICE).
Who is sponsoring clinical trial NCT02031237?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02031237 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02031237's enrollment target sits among peer trials
52 27th of 67 higher than 41 of 67 other Brain Metastases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain Metastases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
RECRUITING · Phase 1
-
Trial of Differential Margins in Single Isocenter Radiosurgery of Brain Metastases
RECRUITING · NA
-
Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer
RECRUITING · Phase 4
-
7T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCLC), Who Decline Prophylactic Cranial Irradiation (PCI)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia